Individualized Medicine
Pharmacogentics
Right Dose. Right Time.
First Time.
Susan Kolyno, BA, CMA,
Vantari Laboratory Representative
medrefer1@gmail.com
Why Pharmacogentics
Avoidable Medical Problem
12
700,000
2.2 MILLION
10
600,000
severe adverse drug reactions per year
8
500,000
400.000
300.000
Column 3
Column 2
Column 1
6
PATIENTS ARE AT RISK
100,000
4
200,000
deaths per year
By PROPERLY PRESCRIBED MEDICATIONS
2
COST LEADER for Mal-Practice
100,000
0
HEA RT
CA NCER
STROKE
RX
CA R CRA SHES
Heart Cancer Stroke RX Car Accidents
If a patient had “double” or “triple hit” genetic variations, wouldn’t
you want to know that prior to their procedure?
Treatment Failures
Prevalent in Disease states
“Keeping in Step”

Cancer
75%

Alzheimers
70%

Arthritis
50%

Diabetic
43%

Asthma
40%

Anti-depressants
38%
“Do No Harm”
GENETIC differences in metabolism = Treatment Failure
More than 100 medications have drug to gene interactions and
are identified in the FDA packet and black box labels
Poly-Pharmacy
Complications in Prescribing
Patients Taking More than 3 Medications
Are you concerned about drug drug interactions and the possibilities
of ADRs or lowered effectiveness of drug regimen?
AT RISK - 40% are over 65
More than 75% of the population have documented genetic variations that
increase their risk for ADR's. Medicines most commonly associated with
ADR's are
8X more likely to go
through pathways with genetic variants.
Considering Patient
Interactions & Safety
Have you experienced incidences with
Pain medications, Anti depressives,
statins or any other drug where it took
several office visits with trial and error
methodology to prescribe the right
medication ? Do your patient’s
depressants inhibit their metabolism
their blood pressure medication?
antiof
How do you prevent that
from reoccurring with your
patients in the future?
If you have been concerned about drug drug interactions and the
possibilities of ADRs or lowered effectiveness of a drug regimen...
the following information will be of interest to you:
Cytochromes
Metabolic Highways
Cytochromes are metabolized in
the liver and intestines. To illustrate,
of these as highways,,,,
drugs as cars on the
the Drugs on that
ONLY be
processed via certain CYPS.
OTC medications, herbal
vitamins and other drugs
levels making it difficult
pass,,,
=
think
and the
highway,,
highway can
only
Genes,
remedies,
change CYP
for the cars to
75% of patients have variations in at least one CYP and do not
metabolize medications normally
Avoiding ADR's
Getting Right the First Time
Pharmacogenetics is the
understanding of how the genetic
variation alters drug response.
Cytochromes (CYPs) are the
metabolic factories in the liver and
intestines.
Poor Metabolizers: Reach maximum
levels very quickly Intermediate
Metabolizers: Half the highway is shut
down, a patient can still metabolize but it is
very difficult. Ultra Metabolizers: Have
additional pathways, these patients never
reach therapeutic effect. Normal
Metabolizers: Have both roads open and
metabolize close to normal.
Changing the Pattern
Will YOU make the Difference?
Interactions involve
cytochromes:
CYP2D6, CYP2C19 & CYP3A4
Individual DNA varies in
Medications and Metabolism
impacting more patients than
Common Genetic testing.
MEDICATION MANAGEMENT
BASED ON PATIENT
METABOLISM
.
Do some of your patients have a variety of undiagnosed issues
that might be related to polymorphic variance of the enzymes
(MTHFR) that regulate Folic acid metabolism ?
2C9,
Why Vantari?
Focus IS On the Patient
Vantari centers it's approach on testing
& hard copy results FOR the PATIENT,,
SPEACILIZING IN PHARMACOGENETICS
Referencing our Partner CPIC, an
independent consortium and 2014 date
publication for physician results & polypharmacy recommendations.
Highly complex CLIA certified.
Simply put,,,”you have now found a reliable
way to screen patients for metabolic
compatibility and avoid Adverse Drug
Reactions, it is worth the protection!”
Test Results - Insurance
In 3-5 Days – No Out of Pocket
Your screening tests and follow-up
are billable.
IF Federal Scrutiny of your prescriptions
IS causing you to lose time while
questioning the uncertainty regarding
the efficacy of certain Pharma products,
billable screenings are the solution.
then
What Do You Think?
Your Opinion Makes a Difference
With Pharmacogentics becoming a recognized medical benefit and
insurance reimbursement management program, would you
want to participate in the "Do No Harm" continuum that is
creating a paradigm shift in the way doctors prescribe medicine?
If the Federal Government recommended Pharmacogentic testing
and CMS agreed to reimburse for this testing why would you
object to implementing it in your office ?
With the Affordable Health Care Act requiring you to work twice as
hard for half the pay, if I could show you how to increase your
bottom line by $110.00 per patient with very little effort on your
part, would that be of interest?"
THERE IS A SIMPLE NO COST SOLUTION
Pharmacy Management
With the movement towards accountable care organizations,,,
CAN you forsee Pharmacogenomics playing a significant role in
reducing your health care cost ?
If you answered YES to any of the
questions throughout this overview,
can help by starting a
we
Trial Pharmacy (run)
Management program
Scientific Review • Diagnose causes for drug related side effects. • Assists the
healthcare provider to select appropriate drug and dose for their patient.
• Achieve optimal therapeutic response. • Minimize side effects of toxicity. • Avoid
therapeutic failure.
No Cost -Trial Pharmacy
Management Program
Complete the simple form with your Vantari
representative:
SET A DATE MONTHLY - Book 10 -15 patients
for an OFF day for screening.
Representative will assist and follow up with billing
or office management.


NO OUT OF POCKET
Compliance Regulated – Request Clinical Studies,
Dossiers, access to CPIC.
YOUR Vantari Team
Accreditations
Nick G. Arroyo -Chief Executive Officer - Nick Arroyo earned his Bachelor of Science Degree in Molecular
Biosciences and Biotechnology from Arizona State University. He began his career working in research in the
Department of Gene and Cellular Therapy at the Arizona Heart Institute where he helped to develop an
investigational stem cell therapy for heart failure and was responsible for the cell manufacturing processes
required for obtaining FDA approval for phase I clinical trial.
Sean Parrish - Chief Operating Officer - Sean Parrish is co-founder of Vantari Genetics and our Chief
Operating Officer. Mr. Parrish's responsibilities encompass national commercialization of our molecular
diagnostics services across the entire value chain from test inception through customer development
and product distribution. Mr. Parrish has been part of the development, launch and marketing strategy
for SimpleCF™, Vantari's cystic fibrosis carrier screening test. Mr. Parrish obtained a Bachelor of
Science degree from the University of Arizona.
Shaun R. Opie, PhDChief Science Officer - Dr. Opie holds a PhD in Biomedical Sciences/Molecular Genetics.
He led all laboratory operations for an investigator initiated Phase I clinical trial using stem cells to treat cardiac
disease and helped develop a proprietary cardiovascular disease gene data set for a publicly traded genomics
company. In addition to clinical trial design and management for FDA regulated investigational new drugs and
devices, Dr. Opie has over 10 years of operations management directing major collaborations with industry and
academic partners in molecular diagnostics research and development. He has held adjunct faculty
appointments in bioengineering and has numerous publications in peer reviewed medical journals and
textbooks.
Phil Lamb -Senior Advisor - Phil has a track record of successfully leading growth businesses into highly
responsive, client-focused service organizations. He provides legal, financial, and strategic advice to the Vantari
Genetic team. In addition to his role with Vantari Genetics, he is also a principal in Infinity Software Solutions, a
leading Human Resources Information System (HRIS). Phil received his J.D. from Harvard Law.
Contact
I can provide case studies, clinical data and insurance
information on pharmacogentics and the impact upon the
medical profession that is NOW changing prescribing
methods rapidly.
Please feel free to contact me with any questions or
individualized studies geared to your practice.
YOUR VANTARI REPRESENTATIVE:
Susan Kolyno
404-989-5084
Website: www.medreferrals.net
RIGHT DOSE. RIGHT TIME. FIRST TIME
Thank You
Right Dose. Right Time.
First Time.
Preventative Patient Care
Susan Kolyno, Account Manager, Vantari Laboratories
423-790-7306 or 404-989-5084